Search
Now showing items 1-2 of 2
Factors influencing delays in patient access to new medicines in Canada: a retrospective study of reimbursement processes in public drug plans
(2019-03-29)
Individuals who rely on public health payers to access new medicines can access fewer innovative medicines and must wait longer in Canada compared to major markets around the world. New medicines/indications approved by ...
Pan-Canadian Pharmaceutical Alliance (pCPA): Timelines Analysis and Policy Implications
(2019-02-18)
This analysis follows our recent study showing that Canadian public reimbursement delays have lengthened from regulatory approval to listing decisions by public drug plans and delayed public access to innovative medicines, ...